Harini Sarva

Columbia University Health Sciences

$447,494

Attributed

$1,342,482

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $469.3K · FY2023–25

$500K$375K$250K$125K$0

'23

'24

'25

Funding mix

By agency

NIH$1,342,482 · 1

By mechanism

U24$1,342,482 · 1

Top collaborators

Claudia A Chiriboga3 shared
Karen S Marder3 shared

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Anil K Rustgi$51,275,906
Mary Beth Terry$27,685,500
George M. Hripcsak$48,919,189
Alfred I Neugut$17,537,198
Claudia A Chiriboga$5,375,833

Others in their field

Other Rising Stars on “Duchenne Muscular Dystrophy”

Forum D Kamdar · University Of Minnesota$2,117,320
Ryan David Wuebbles · Strykagen Corporation$1,953,245
Alexis R. Demonbreun · Northwestern University At Chicago$1,558,118
David W Hammers · University Of Florida$1,392,499
Daniel Kopinke · University Of Florida$1,327,925
Russell Rogers · Cedars-Sinai Medical Center$1,153,657

Research focus

Duchenne Muscular DystrophyAcademic Medical CentersDoseAntisense OligonucleotidesAppointmentAdvocateAmyotrophic Lateral SclerosisAdultBiological MarkersBiomarker ValidationChildhoodClinical CenterClinical Research SiteClinical TrialsCollaborationsAwardCommunity EngagementBinding SitesCommunity TrialConduct Clinical TrialsContinuity Of Patient CareDedicationsDesignEarly Phase Trial

Grant awards (3)

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)$439,931

U24 · FY2025 · NS

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)$433,251

U24 · FY2024 · NS

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)$469,300

U24 · FY2023 · NS